Moderna (NASDAQ:MRNA) today reported fourth-quarter results that beat the Wall Street consensus on revenue but missed on earnings. Demand for the company’s COVID-19 vaccines is down, and there is surplus production capacity. Investors reacted by sending MRNA shares down more than 1% to $156.51 apiece in morning trading. Q4 2022 Q4 2021 Change Revenue $5.1…
Qosina appoints former EssilorLuxottica exec as its EVP
Qosina announced today that it’s appointed Lee Pochter as its executive vice president. Pochter has more than 20 years of expertise in product strategy, business development, sales, marketing and supply chain management. Most recently, he was VP of the Alternative Lens Group at EssilorLuxottica. “I look forward to the guidance Lee will bring to our…
Tablet press maker Korsch acquires Medelpharm to boost R&D offerings
Korsch AG recently announced that has acquired Medelpharm and its compaction simulator technology. The financial terms of the deal were not disclosed. Korsch said Medelpharm’s compaction simulator technology adds early-stage material characterization and scale-up capability to its R&D product portfolio. The companies have 135-plus years of experience with small-scale, fully instrumented tablet compression equipment. The Korsch…
Johnson & Johnson reports mixed Q4 results amid shaky economy
Johnson & Johnson (NYSE:JNJ) today reported Q4 results that beat The Street on earnings but missed on revenue amid continued macroeconomic challenges. The company’s Pharmaceutical business saw sales grow 6.8%. Pharma growth drivers included: Darzalex (daratumumab), a biologic for the treatment of multiple myeloma; Stelara (ustekinumab), a biologic for the treatment of a number of…
Agilent spends $725M to expand manufacturing
Agilent recently announced that it plans to double its manufacturing capacity of therapeutic nucleic acids. The $725 million investment will go toward the Santa Clara, California–based company’s Frederick, Colorado facility. The Colorado plant will get new Train C and D manufacturing lines. The facility already has a Train B manufacturing line, announced in 2020, that…
MasterControl raises $150M to support its quality and manufacturing software
MasterControl (Salt Lake City) today announced a $150 million Series A round led by Sixth Street Growth, with a company valuation of $1.3 billion. The money raised will accelerate the development of its quality and manufacturing software as a service offerings serving life sciences customers. MasterControl’s customers include such giants as Pfizer, Cochlear and Thermo Fisher…
Cardinal Health beats The Street in Q1 — with pharma sales up 15%
Cardinal Health (NYSE: CAH) today reported first-quarter results that beat the consensus forecast on Wall Street, sticking by its full-year EPS guidance. The Dublin, Ohio–based pharma and medtech giant earned $110 million, or 40¢ per share, off $49.6 billion in revenue for the quarter ended Sept. 30, 2022. The bottom line was less than half…
BD secures ISO certification for its information security management system
BD announced today that it has secured ISO certification for its enterprise-level Information Security Management System. The Franklin Lakes, New Jersey–based company said the ISMS meets a rigorous set of independently audited international standards. BD says the ISO/IEC 27001:2022 certification demonstrates its commitment to protecting the company, customers and patients from cybersecurity threats. The International…
Biogen beats The Street in Q3 — but revenue down 10%
Biogen (Nasdaq: BIIB) today reported third-quarter results that beat the expectations of Wall Street analysts, upping its full-year guidance. The Cambridge, Massachusetts–based neurological biotech company earned $1.1 billion, or $7.84 per share, off $2.5 billion in revenue for the quarter ended Sept. 30, 2022. It more than tripled its bottom line even as the top…
Grifols kicks off new albumin plant in Dublin
Grifols today is inaugurating a new albumin purification and filling plant at its manufacturing and supply hub in Dublin. Barcelona, Spain–based Grifols said the new facility addresses the growing demand for the plasma-derived medicine. The newly built plant adds more than 183,000 square feet to Grifols’ Dublin facilities. The workforce will increase from 300 to…